CHINA RESOURCES MEDICAL HOLDINGS COMPANY LIMITED Financials China Resources Medical Holdings Company Limited
Equities
1515
KYG2133W1087
Healthcare Facilities & Services
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.25 HKD | +2.41% |
|
+0.47% | -11.83% |
| 04-26 | China Resources Medical's 2023 Profit Slides | MT |
| 03-19 | China Resources Medical Holdings Company Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 19 July 2024 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 5,238 | 7,268 | 4,902 | 6,596 | 5,681 | 5,096 | - | - |
| Enterprise Value (EV) 1 | 3,804 | 5,265 | 3,996 | 5,315 | 5,681 | 4,520 | 3,607 | 2,155 |
| P/E ratio | 13 x | 22.4 x | 11.5 x | 46.2 x | 21.9 x | 8.02 x | 6.09 x | 5.46 x |
| Yield | 2.25% | 1.57% | 2.59% | 0.63% | - | 3.48% | 4.47% | 4.33% |
| Capitalization / Revenue | 2.48 x | 2.64 x | 1.1 x | 1.17 x | 0.56 x | 0.47 x | 0.44 x | 0.43 x |
| EV / Revenue | 1.8 x | 1.91 x | 0.9 x | 0.95 x | 0.56 x | 0.42 x | 0.31 x | 0.18 x |
| EV / EBITDA | 6.65 x | 12.8 x | 6.36 x | 8.11 x | 3.68 x | 2.85 x | 2.01 x | 1.19 x |
| EV / FCF | 11,537,221 x | 12,127,397 x | 7,804,422 x | 14,221,763 x | - | - | - | - |
| FCF Yield | 0% | 0% | 0% | 0% | - | - | - | - |
| Price to Book | 0.86 x | 1.15 x | 0.74 x | 1.02 x | - | 0.79 x | 0.72 x | 0.65 x |
| Nbr of stocks (in thousands) | 1,296,677 | 1,296,677 | 1,296,677 | 1,296,677 | 1,296,677 | 1,296,677 | - | - |
| Reference price 2 | 4.039 | 5.605 | 3.781 | 5.087 | 4.381 | 3.930 | 3.930 | 3.930 |
| Announcement Date | 24/03/20 | 26/03/21 | 25/03/22 | 28/03/23 | 19/03/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2,115 | 2,751 | 4,447 | 5,620 | 10,108 | 10,806 | 11,594 | 11,913 |
| EBITDA 1 | 572.4 | 411.9 | 628.2 | 655.3 | 1,543 | 1,584 | 1,797 | 1,805 |
| EBIT 1 | 508.7 | 298.5 | 445.3 | 322.9 | 932.3 | 1,034 | 1,269 | 1,300 |
| Operating Margin | 24.05% | 10.85% | 10.01% | 5.74% | 9.22% | 9.57% | 10.94% | 10.91% |
| Earnings before Tax (EBT) 1 | 541.3 | 418.2 | 270.5 | 242.4 | 492.9 | 1,029 | 1,267 | 1,287 |
| Net income 1 | 390.9 | 310.1 | 417.9 | 139 | 257.7 | 672.1 | 817.5 | 881.2 |
| Net margin | 18.48% | 11.27% | 9.4% | 2.47% | 2.55% | 6.22% | 7.05% | 7.4% |
| EPS 2 | 0.3100 | 0.2500 | 0.3300 | 0.1100 | 0.2000 | 0.4900 | 0.6449 | 0.7200 |
| Free Cash Flow | 329.7 | 434.1 | 512 | 373.7 | - | - | - | - |
| FCF margin | 15.59% | 15.78% | 11.51% | 6.65% | - | - | - | - |
| FCF Conversion (EBITDA) | 57.6% | 105.39% | 81.5% | 57.03% | - | - | - | - |
| FCF Conversion (Net income) | 84.35% | 139.99% | 122.51% | 268.91% | - | - | - | - |
| Dividend per Share 2 | 0.0911 | 0.0882 | 0.0980 | 0.0320 | - | 0.1367 | 0.1758 | 0.1700 |
| Announcement Date | 24/03/20 | 26/03/21 | 25/03/22 | 28/03/23 | 19/03/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 S1 |
|---|---|
| Net sales 1 | 5,114 |
| EBITDA | - |
| EBIT | - |
| Operating Margin | - |
| Earnings before Tax (EBT) | - |
| Net income 1 | 397.7 |
| Net margin | 7.78% |
| EPS | - |
| Dividend per Share | - |
| Announcement Date | 22/08/23 |
1CNY in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 1,434 | 2,003 | 907 | 1,281 | - | 576 | 1,489 | 2,941 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | 330 | 434 | 512 | 374 | - | - | - | - |
| ROE (net income / shareholders' equity) | 6.8% | 5.16% | 6.66% | 3.26% | - | 11.1% | 11.7% | 11.9% |
| ROA (Net income/ Total Assets) | 5.15% | 3.68% | 4.3% | 1.29% | - | 4.5% | 5.2% | 6% |
| Assets 1 | 7,597 | 8,419 | 9,714 | 10,786 | - | 14,935 | 15,721 | 14,687 |
| Book Value Per Share 2 | 4.710 | 4.860 | 5.140 | 4.980 | - | 4.990 | 5.460 | 6.070 |
| Cash Flow per Share 2 | 0.2900 | 0.5100 | 0.5600 | 0.5000 | - | 1.060 | 1.210 | 1.110 |
| Capex 1 | 36.4 | 210 | 198 | 253 | - | 525 | 678 | 99 |
| Capex / Sales | 1.72% | 7.62% | 4.46% | 4.5% | - | 4.86% | 5.84% | 0.83% |
| Announcement Date | 24/03/20 | 26/03/21 | 25/03/22 | 28/03/23 | 19/03/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
3.93
CNY
Average target price
5.666
CNY
Spread / Average Target
+44.17%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -11.83% | 705M | |
| -18.90% | 16.51B | |
| +4.50% | 12.53B | |
| +4.81% | 11.74B | |
| +2.43% | 10.06B | |
| -4.75% | 7.57B | |
| +21.11% | 7.22B | |
| +5.46% | 6.68B | |
| +45.72% | 4.54B | |
| -3.49% | 4.32B |
- Stock Market
- Equities
- 1515 Stock
- Financials China Resources Medical Holdings Company Limited
